TrialDiabetes, obesity & metabolism2026

Efficacy and safety of bi-weekly cofrogliptin treatment replacing daily dipeptidyl peptidase-4 inhibitors in Chinese patients with type 2 diabetes mellitus: A multicenter, open-label, randomized controlled phase 2 trial.

Congqing Pan et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.